FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab

Table 2 Changes in FLT SUVs, RECIST size measurements, and PSA levels from baseline to 12 weeks were included in Cox proportional hazards regression models to assess association with progression-free survival time

	Predictor	C-index^a	C-index P value	Hazard Ratio	HR P value	N^b
Traditional markers of response	Change PSA	0.72 (0.50 to 0.94)	0.05	2.34 (1.18 to 4.62)	0.01	17 (12)
Traditional markers of response	Change soft tissue tumor size (RECIST)	0.59 (0.54 to 0.63)	< 0.01	1.78 (0.60 to 5.29)	0.30	7 (6)
FLT PET changes in lymphoid organs	Change left axillary lymph node SUV_mean	0.70 (0.48 to 0.91)	0.07	0.89 (0.43 to 1.84)	0.75	16 (11)
	Change spleen SUV_mean	0.73 (0.56 to 0.90)	0.01	2.14 (1.11 to 4.12)	0.02	16 (11)
	Change bone marrow SUV_mean	0.65 (0.41 to 0.89)	0.22	1.94 (0.98 to 3.86)	0.06	17 (12)
FLT PET changes in tumors	Change tumor SUV_mean	0.83 (0.71 to 0.95)	< 0.01	3.38 (1.01 to 11.28)	0.05	10 (8)
FLT PET changes in tumors	Change tumor SUV_total	0.69 (0.59 to 0.79)	< 0.01	1.53 (0.76 to 3.10)	0.24	10 (8)

^aConcordance index (95% confidence interval shown in parenthesis)
^bN = number of patients included in calculation (value in parenthesis is number of patients that were not censored)